Illumina, Inc. (NASDAQ:ILMN) insider Michel Bouchard sold 5,390 shares of the stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $202.11, for a total value of $1,089,372.90. Following the sale, the insider now owns 15,161 shares of the company’s stock, valued at approximately $3,064,189.71. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Michel Bouchard also recently made the following trade(s):

  • On Wednesday, August 30th, Michel Bouchard sold 616 shares of Illumina stock. The shares were sold at an average price of $200.00, for a total value of $123,200.00.
  • On Wednesday, August 2nd, Michel Bouchard sold 3,131 shares of Illumina stock. The shares were sold at an average price of $194.97, for a total value of $610,451.07.
  • On Friday, June 23rd, Michel Bouchard sold 246 shares of Illumina stock. The shares were sold at an average price of $185.00, for a total value of $45,510.00.
  • On Thursday, June 8th, Michel Bouchard sold 246 shares of Illumina stock. The shares were sold at an average price of $178.91, for a total value of $44,011.86.

Illumina, Inc. (NASDAQ ILMN) traded up 1.32% during trading on Friday, reaching $207.15. 824,564 shares of the company’s stock traded hands. The firm has a 50 day moving average price of $186.97 and a 200-day moving average price of $177.03. The firm has a market cap of $30.24 billion, a PE ratio of 41.56 and a beta of 0.83. Illumina, Inc. has a 12 month low of $119.37 and a 12 month high of $207.49.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The firm had revenue of $662 million for the quarter, compared to analyst estimates of $642.38 million. During the same period in the previous year, the business earned $0.86 EPS. The company’s revenue was up 10.3% compared to the same quarter last year. On average, analysts forecast that Illumina, Inc. will post $3.65 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.watchlistnews.com/insider-selling-illumina-inc-ilmn-insider-sells-5390-shares-of-stock/1536765.html.

A number of equities research analysts have recently commented on ILMN shares. Deutsche Bank AG set a $175.00 price objective on Illumina and gave the company a “hold” rating in a research report on Friday, July 28th. Canaccord Genuity upgraded Illumina from a “hold” rating to a “buy” rating and increased their price objective for the company from $170.00 to $215.00 in a research report on Monday, August 7th. Morgan Stanley reiterated an “underweight” rating and set a $122.00 price objective (up previously from $115.00) on shares of Illumina in a research report on Monday, July 10th. Vetr downgraded Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price objective for the company. in a research report on Wednesday, June 21st. Finally, Barclays PLC reiterated a “hold” rating and set a $150.00 price objective on shares of Illumina in a research report on Wednesday, July 19th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $177.01.

Large investors have recently modified their holdings of the stock. Advisory Services Network LLC purchased a new position in Illumina during the first quarter valued at $117,000. Penserra Capital Management LLC raised its position in Illumina by 13.0% in the second quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock valued at $153,000 after buying an additional 102 shares in the last quarter. Paradigm Asset Management Co. LLC raised its position in Illumina by 5.6% in the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after buying an additional 50 shares in the last quarter. Patten Group Inc. raised its position in Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after buying an additional 25 shares in the last quarter. Finally, NN Investment Partners Holdings N.V. raised its position in Illumina by 11.3% in the second quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock valued at $171,000 after buying an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 93.32% of the company’s stock.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.